- This event has passed.
European CNS Summit 2016 – BioChem Adda
September 12, 2016 - September 14, 2016
European CNS Summit 2016: The European CNS Summit 2016 will build on the success of the 4th annual World CNS Summit 2016, with an exclusive focus on empowering translational research in the field of neurodegeneration.
European CNS Summit 2016
This is a unique opportunity to engage with the thought leaders in the neurodegenerative space from academia, pharma, biotech and leading consortia to advance the successful development of the next generation of therapies.
The increasing prevalence of dementia and other neurodegenerative disorders represents the greatest threat to public healthcare over the coming decades. Despite the level of investment in this space, the arsenal of effective therapies remains bare. However, significant progress is being made in both pre-clinical and clinical research to translate advances in the understanding of disease etiology and pathogenesis into the discovery and development of potent therapeutics.
The European CNS Summit 2016 is your chance to challenge traditional thinking to reinvigorate drug discovery and development across multiple neurodegenerative disorders.
Following the highly successful World CNS Summit: Targeting Neurodegenerative Diseases, this meeting will once again bring together the brightest minds in the field to:
- Advance translational biomarker discovery from target engagement to disease progression
- Harness innovation in novel therapeutic strategies targeting neurodegeneration to progress disease modifying therapies
- Enhance patient identification and stratification to inform translational research programmes and improve the success of clinical studies
- De-risk later phase clinical trials through the correct utilisation of target engagement studies
- Redefine the use of pre-clinical models of neurodegeneration to enhance their application in translational research
Use this collaborative format to address key challenges facing this field from the translatability of modelling systems to the development of cost effective, non-invasive biomarkers and novel therapeutic strategies for targeting neurodegeneration.